Allergy Therapeutics Advances VLP Peanut Study: A Potential Breakthrough in Allergy Treatment

Allergy Therapeutics ((GB:AGY)), Allergy Therapeutics US ((AGYTF)) announced an update on their ongoing clinical study.

Study Overview: Allergy Therapeutics is conducting a Phase I clinical trial titled ‘A Phase I Clinical Trial to Evaluate the Safety and Tolerability of VLP Peanut in Healthy Subjects and Subjects With Peanut Allergy and to Explore Preliminary Signals of Its Efficacy (PROTECT)’. The study aims to assess the safety, tolerability, and preliminary efficacy of VLP Peanut, a potential treatment for peanut allergies, which could significantly impact the management of this common allergy.

Intervention/Treatment: The trial is testing VLP Peanut, a biological intervention administered subcutaneously and through skin-prick tests. It is designed to evaluate its safety and potential efficacy in reducing allergic reactions to peanuts.

Study Design: This interventional study is randomized and follows a sequential model. It includes an open-label Part A for healthy and peanut-allergic subjects and a double-blind, placebo-controlled Part B for peanut-allergic subjects. The primary purpose is treatment, with masking for participants, care providers, investigators, and outcomes assessors in Part B.

Study Timeline: The study began on October 17, 2022, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 11, 2025, indicating ongoing progress.

Market Implications: This study’s progress could positively influence Allergy Therapeutics’ stock performance by showcasing potential advancements in peanut allergy treatments. As the company competes in a growing market for allergy treatments, successful results may enhance investor confidence and position the company favorably against competitors.

The study is currently recruiting, with further details available on the ClinicalTrials portal.